Our BRC has the largest portfolio of early phase clinical trials, according to recently published performance figures.
Early phase trials are carried out in small groups of patients and commonly aim to assess the safe dose range, side effects and early indications of the efficacy of novel therapies.
They are a particular strength of UCLH/UCL given the scientific strengths and clinical expertise of the partnership. The performance figures, that were derived from the NIHR’s recent analysis of the BRCs’ annual reports for 2011/12, are a clear sign that the BRC’s focus on experimental medicine is enabling the partnership to make a step change in its capacity to initiate and deliver new phase I and II trials.
